Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1RAs have transformed the treatment of type 2 diabetes and obesity. However, adverse effects, cost, access, treatment burden, and weight regain after drug withdrawal highlight the need to investigate durable complementary strategies. Duodenal mucosal resurfacing (DMR) modifies maladaptive duodenal signaling via controlled mucosal injury and regeneration. In the sham-controlled REVITA-2 trial, hydrothermal DMR did not significantly improve glycated hemoglobin or liver fat in the overall population, although prespecified European analyses suggested metabolic benefit. Small open-label studies combining hydrothermal DMR or recellularization using electroporation therapy with GLP-1RA treatment reported insulin discontinuation in selected patients, but the procedural contribution could not be separated from pharmacotherapy and lifestyle interventions. Thus, it remains unproven whether duodenal intervention can maintain metabolic benefits after GLP-1RA withdrawal. Emerging systems differ substantially in energy source, tissue target, procedural workflow, and safety profile. A delayed perforation after laser ablation underscores the integral role of dosimetry, catheter stability, insufflation, and surveillance in safety. At present, duodenal mucosal interventions should be confined to clinical trials. Randomized sham-controlled studies with standardized background therapy, clinically relevant safety outcomes, and long-term follow-up are necessary to define their complementary role in the incretin era.
No takes yet. Share an insight, caveat, or question.
Su Jin Kim (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: